InnoCare Pharma Ltd. A (688428) - Total Liabilities
Based on the latest financial reports, InnoCare Pharma Ltd. A (688428) has total liabilities worth CN¥2.65 Billion CNY as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InnoCare Pharma Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how InnoCare Pharma Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
InnoCare Pharma Ltd. A Competitors by Total Liabilities
The table below lists competitors of InnoCare Pharma Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Changzhou NRB Corp
SHE:002708
|
China | CN¥2.03 Billion |
|
Suzhou Wanxiang Technology Co. Ltd.
SHE:301180
|
China | CN¥609.82 Million |
|
Brim hf
IC:BRIM
|
Iceland | Ikr477.84 Million |
|
Orezone Gold Corp
TO:ORE
|
Canada | CA$255.87 Million |
|
Jiangsu Libert Inc
SHG:605167
|
China | CN¥2.53 Billion |
|
Zhenjiang Dongfang Electric Heat
SHE:300217
|
China | CN¥2.05 Billion |
|
Tuya Inc.
F:7850
|
Germany | €127.61 Million |
|
Denka Company Limited
F:DIK
|
Germany | €325.80 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down InnoCare Pharma Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InnoCare Pharma Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InnoCare Pharma Ltd. A (2020–2024)
The table below shows the annual total liabilities of InnoCare Pharma Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.66 Billion | -2.81% |
| 2023-12-31 | CN¥2.74 Billion | +2.30% |
| 2022-12-31 | CN¥2.68 Billion | +53.96% |
| 2021-12-31 | CN¥1.74 Billion | +26.24% |
| 2020-12-31 | CN¥1.38 Billion | -- |
About InnoCare Pharma Ltd. A
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone l… Read more